- Home
- RMCF vs INTS Comparison
RMCF vs INTS Comparison
Compare RMCF & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- INTS
- Stock Information
- Founded
- RMCF 1981
- INTS 2012
- Country
- RMCF United States
- INTS United States
- Employees
- RMCF N/A
- INTS N/A
- Industry
- RMCF Specialty Foods
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- INTS Health Care
- Exchange
- RMCF Nasdaq
- INTS Nasdaq
- Market Cap
- RMCF 9.4M
- INTS 8.4M
- IPO Year
- RMCF N/A
- INTS 2023
- Fundamental
- Price
- RMCF $1.66
- INTS $0.24
- Analyst Decision
- RMCF
- INTS Strong Buy
- Analyst Count
- RMCF 0
- INTS 2
- Target Price
- RMCF N/A
- INTS $6.75
- AVG Volume (30 Days)
- RMCF 57.0K
- INTS 6.2M
- Earning Date
- RMCF 07-15-2025
- INTS 08-11-2025
- Dividend Yield
- RMCF N/A
- INTS N/A
- EPS Growth
- RMCF N/A
- INTS N/A
- EPS
- RMCF N/A
- INTS N/A
- Revenue
- RMCF $29,545,000.00
- INTS N/A
- Revenue This Year
- RMCF N/A
- INTS N/A
- Revenue Next Year
- RMCF N/A
- INTS N/A
- P/E Ratio
- RMCF N/A
- INTS N/A
- Revenue Growth
- RMCF 5.81
- INTS N/A
- 52 Week Low
- RMCF $1.12
- INTS $0.19
- 52 Week High
- RMCF $3.49
- INTS $4.94
- Technical
- Relative Strength Index (RSI)
- RMCF 48.22
- INTS 30.38
- Support Level
- RMCF $1.73
- INTS $0.32
- Resistance Level
- RMCF $2.07
- INTS $0.36
- Average True Range (ATR)
- RMCF 0.19
- INTS 0.03
- MACD
- RMCF -0.04
- INTS -0.00
- Stochastic Oscillator
- RMCF 1.67
- INTS 30.74
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.